Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
11.42 | 2.98% | 0.33 |
ALNA closed up 2.98 percent on Thursday, September 20, 2018, on approximately normal volume. It was able to find support at its 50 day moving average. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| See historical ALNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | 50 DMA Support | Bullish | 0.00% |
| Sep 20 | Crossed Above 200 DMA | Bullish | 0.00% |
| Sep 20 | BB Squeeze Ended | Range Expansion | 0.00% |
| Sep 20 | Above Upper BB | Strength | 0.00% |
| Sep 20 | Up 3 Days in a Row | Strength | 0.00% |
| Sep 20 | Upper Bollinger Band Touch | Strength | 0.00% |
| Sep 19 | Crossed Above 20 DMA | Bullish | 2.98% |
| Sep 19 | Crossed Above 50 DMA | Bullish | 2.98% |
| Sep 19 | MACD Bullish Signal Line Cross | Bullish | 2.98% |
| Sep 19 | Bollinger Band Squeeze | Range Contraction | 2.98% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-14
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ALNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 17.56 |
| 52 Week Low | 6.13 |
| Average Volume | 68,068 |
| 200-Day Moving Average | 11.3987 |
| 50-Day Moving Average | 10.809 |
| 20-Day Moving Average | 10.778 |
| 10-Day Moving Average | 10.742 |
| Average True Range | 0.8006 |
| ADX | 17.78 |
| +DI | 25.8809 |
| -DI | 11.6088 |
| Chandelier Exit (Long, 3 ATRs ) | 9.5982 |
| Chandelier Exit (Short, 3 ATRs ) | 12.6118 |
| Upper Bollinger Band | 11.3872 |
| Lower Bollinger Band | 10.1688 |
| Percent B (%b) | 1.03 |
| BandWidth | 11.304509 |
| MACD Line | -0.0175 |
| MACD Signal Line | -0.0957 |
| MACD Histogram | 0.0781 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.83 | ||||
| Resistance 3 (R3) | 12.78 | 12.26 | 12.60 | ||
| Resistance 2 (R2) | 12.26 | 11.90 | 12.29 | 12.52 | |
| Resistance 1 (R1) | 11.84 | 11.68 | 12.05 | 11.89 | 12.44 |
| Pivot Point | 11.32 | 11.32 | 11.43 | 11.35 | 11.32 |
| Support 1 (S1) | 10.90 | 10.96 | 11.11 | 10.95 | 10.40 |
| Support 2 (S2) | 10.38 | 10.74 | 10.41 | 10.32 | |
| Support 3 (S3) | 9.96 | 10.38 | 10.25 | ||
| Support 4 (S4) | 10.01 |
